GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (FRA:PGO0) » Definitions » YoY EBITDA Growth

Prostatype Genomics AB (FRA:PGO0) YoY EBITDA Growth : 100.00% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Prostatype Genomics AB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Prostatype Genomics AB's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 100.00%.

Prostatype Genomics AB's EBITDA per Share for the three months ended in Jun. 2024 was €0.00.

Prostatype Genomics AB YoY EBITDA Growth Historical Data

The historical data trend for Prostatype Genomics AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB YoY EBITDA Growth Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
YoY EBITDA Growth
- 16.86 -27.32 -522.57 68.36

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.05 10.30 83.97 100.00 100.00

Prostatype Genomics AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Prostatype Genomics AB's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-19.762--62.462)/ | -62.462 |
=68.36 %

Prostatype Genomics AB's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(0--3.075)/ | -3.075 |
=100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (FRA:PGO0) » Definitions » YoY EBITDA Growth
Comparable Companies
XSAT:SPERM OSTO:IMMNOV XSAT:GEAN XSAT:ALPH XSAT:CALMA B NGM:ATANA OSTO:AROC TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX WAT
Traded in Other Exchanges
PROGEN:Sweden
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Website
https://www.prostatypegenomics.com
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB Headlines

No Headlines